Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
04 2020
Historique:
received: 03 06 2019
revised: 20 07 2019
accepted: 31 07 2019
pubmed: 1 9 2019
medline: 22 4 2021
entrez: 1 9 2019
Statut: ppublish

Résumé

To assess the influence of rheumatoid arthritis (RA) disease activity (DA) on the risk of aseptic loosening after total hip/knee arthroplasty (THA/TKA). We identified RA patients who underwent THA/TKA and determined their DA using the simplified disease activity index (SDAI). The risk of aseptic loosening was estimated using radiographic signs of component loosening (RCL). We performed Cox regression to estimate RCL based on SDAI, adjusting for therapy. We also investigated a cohort of 2:1 matched osteoarthritis (OA) patients as a control group without systemic inflammation. We identified 49 RA patients with a history of THA/TKA, of whom 18 (36.7%) showed RCL. SDAI over time was significantly higher in patients with RCL (median; 25th and 75th percentile: 10.8 months; 8.6 and 15.8; vs 7.0 months; 2.7 and 15.5;p = 0.043). In the regression model, each unit of mean SDAI over time significantly increased the risk of RCL (HR 1.125, 95% CI 1.021-1.241;p = 0.018). Patients treated with biological had a lower risk of RCL than those treated with traditional DMARDs (HR 0.192, 95% CI 0.042-0.891;p = 0.035). In the 88 matched OA patients, the RCL rate was significantly lower than in the RA group (13.6%;p = 0.002). Higher inflammatory DA increases the risk for radiographic loosening after THA/TKA in patients with RA. The significantly lower risk in patients with OA further underlines the potential role of inflammatory DA. In the context of treating RA to target, the presence of an arthroplasty might be considered as an indication for more stringent control of DA.

Identifiants

pubmed: 31471012
pii: S0049-0172(19)30374-9
doi: 10.1016/j.semarthrit.2019.07.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-251

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Christoph Böhler (C)

Department of Orthopaedics and Trauma Surgery, Medical University of Vienna, Division of Orthopaedics, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Peter Weimann (P)

Department of Orthopaedics and Trauma Surgery, Medical University of Vienna, Division of Orthopaedics, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Farideh Alasti (F)

Department of Medicine 3, Medical University of Vienna, Division of Rheumatology, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Josef S Smolen (JS)

Department of Medicine 3, Medical University of Vienna, Division of Rheumatology, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Reinhard Windhager (R)

Department of Orthopaedics and Trauma Surgery, Medical University of Vienna, Division of Orthopaedics, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Daniel Aletaha (D)

Department of Medicine 3, Medical University of Vienna, Division of Rheumatology, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address: daniel.aletaha@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH